EN DE
STOCK COMPARISON

AstraZeneca vs Eli Lilly and: Fair Value & Quality

Both stocks run through our valuation models. Here is how AstraZeneca (AZN) and Eli Lilly and (LLY) compare, as of Aug 8, 2026.

As of Aug 8, 2026, Fair Value Calculator sees AstraZeneca as the less overvalued of the two: AstraZeneca trades at $161 versus a fair value of $130 (-20%), while Eli Lilly and trades at $1,192 versus $397 (-67%).
AstraZeneca
AZN · USD · Health Care
-20%
upside to fair value
overvalued
Price$161
Fair Value$130
Quality66/100
Eli Lilly and
LLY · USD · Health Care
-67%
upside to fair value
overvalued
Price$1,192
Fair Value$397
Quality75/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

AstraZenecaEli Lilly and
Valuation
26.3×P/E (TTM)42.2×
4.49×P/S (TTM)14.67×
5.58×P/B39.94×
14.5×EV/EBITDA30.2×
1.36×PEG1.54×
1.8%Dividend yield0.5%
$3.20Dividend per share$6.23
Profitability
17%Net margin35%
28%Operating margin49%
23%Return on equity107%
8%Return on assets21%
Growth
13%Revenue growth (YoY)56%
9.8%Avg. growth/yr (3Y)31.7%
17.2%Avg. growth/yr (5Y)21.6%
Balance & size
0.51×Debt / equity1.54×
$271BMarket cap$1.1T
healthyGrowth qualitymixed

Even match: 7 to 7 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

AstraZenecaof which business quality 65 · market factors 52 Eli Lilly andof which business quality 65 · market factors 81
ProfitabilityMargins and returns on capital today
63
85
Quality GrowthAre margins and returns improving?
65
86
CashflowEarnings quality: real cash, not paper profit
63
51
Fin. StrengthBalance sheet, leverage, solvency risk
60
53
InvestmentDisciplined investing over empire-building
60
15
Low VolatilityCalm price path (market factor)
84
73
MomentumPrice trend over the last 3–12 months (market factor)
38
78
52W MomentumDistance to the 52-week high (market factor)
40
94
Net IssuanceBuybacks instead of dilution
82
93

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

AstraZeneca

DCF Models$112
Earnings-Based$60.23
Multiples$113
Asset-Based$21.03
Growth DCF$92.46
Economic Profit$75.73
Growth Earnings$119

24 of 24 models see the stock below the current price.

Eli Lilly and

DCF Models$323
Earnings-Based$239
Dividend Discount$115
Multiples$303
Asset-Based$19.94
Growth DCF$171
Economic Profit$347
Growth Earnings$353

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

AstraZeneca
Bear $73.72Fair Value $130Bull $173
$161 = current price (white tick)
Eli Lilly and
Bear $222Fair Value $397Bull $582
$1,192 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

AstraZeneca · Health Care

Quality score66 · Top 25%
Fair value upside-20% · above median

Eli Lilly and · Health Care

Quality score75 · Top 25%
Fair value upside-67% · bottom 25%

Bottom line

As of Aug 8, 2026, Fair Value Calculator sees AstraZeneca as the less overvalued of the two: AstraZeneca trades at $161 versus a fair value of $130 (-20%), while Eli Lilly and trades at $1,192 versus $397 (-67%).

Eli Lilly and has the higher quality score (75/100).

See the full analysis →
AstraZeneca · Eli Lilly and

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to AstraZeneca

UnitedHealth Group vs AstraZenecaEli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth Group

Related to Eli Lilly and

UnitedHealth Group vs Merck & CompanyUnitedHealth Group vs Thermo Fisher ScientificUnitedHealth Group vs AmgenUnitedHealth Group vs Abbott Laboratories
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.